Physician profile
Bethanie M Simmons Becil
NPI 1497058879
$782,327.34
in general payments reported to CMS, 2019-2025
15 companies · $220K in 2025
The $220K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78K · 2022: $118K · 2023: $154K · 2024: $213K · 2025: $220K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $367K · Honoraria: $75K · Consulting Fee: $71K · Travel and Lodging: $59K · Food and Beverage: $15K · Education: $5.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $366,975.00 |
| Honoraria | $74,921.00 |
| Consulting Fee | $70,578.96 |
| Travel and Lodging | $58,756.33 |
| Food and Beverage | $15,186.23 |
| Education | $5.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609,803.70 | 2021-2025 | |
| Axsome Therapeutics, INC. | $166,475.43 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $5,438.56 | 2021 | |
| Corium, LLC | $174.54 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $158.55 | 2021-2024 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $61.74 | 2023-2024 | Trintellix |
| Neos Therapeutics, Lp | $45.80 | 2025 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.95 | 2024 | Caplyta |
| Tris Pharma INC | $28.00 | 2024-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $21.52 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $21.23 | 2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $18.70 | 2024 | Ingrezza |
| Almatica Pharma LLC | $17.03 | 2024 | Loreev Xr |
| Noven Pharmaceuticals, INC. | $16.34 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $16.25 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethanie Simmons Becil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.